Add Yahoo as a preferred source to see more of our stories on Google. Unlike typical glaucoma treatments that slow progression, this approach aims to rejuvenate the retinal ganglion cells that die ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

Life runs on information. In living systems, that information takes two main forms: the genome and the epigenome. The genome stays mostly stable. The epigenome, however, constantly shifts, shaped by ...

For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.

The idea that cells could be reset emerged from decades of research in regenerative medicine. The field traces back to 1962, ...

For decades, the idea of a drug that could rewind aspects of human aging has belonged more to science fiction than hospital formularies. That boundary is starting to blur as a gene therapy called ...

The US Food and Drug Administration (FDA) has approved a Phase 1 clinical trial from Life Biosciences that aims to help certain eye cells act younger and improve vision in glaucoma and related ...

From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...

In this excerpt from “We Are As Gods: A Survival God for the Age of Abundance,” authors Peter H. Diamandis and Steven Kotler ...

Beyond headlines and promises of eternal youth, advances in transplants, epigenetic clocks, and cellular reprogramming are redefining aging to help people live longer — and, above all, healthier. Some ...

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in ...